We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Status: Active

Nov 15th 2019 - Nov 30th 2019

Hussle is one of the UK's top fitness marketplace, providing many flexible fitness opportunities according to your requirement. The company has provided c.2.5M gym visits, raised £12M+ to date, and serviced more than 500k customers. The platform has c.40% of UK gyms and c.3,000 fitness venues. Besides a huge customer base, 10,000 new members are added to the facility each month. It has received a rating of 4.7 stars out of 5 on TrustPilot across 1,500 reviews. So far, Hussle has raised £12M+ from Albion, MMC, Concentric, TechnoGym, and Channel 4. With the proceeds, the company aims at creating a globally trusted fitness brand by enhancing the brand's awareness and by broadening the range of physical activities available on the platform.

read more read less

Hussle Rating Review

Pitch rating powered by CROWDRATING

Rated on 09/12/2019

Pitch Rated

53%

Insufficient Data

Management

83%

Product

75%

Investment

UNRATED*

* Section unrated owing to insufficient or incomplete information available at the time of rating.

Log in to view amount pledged

    Log in to view target

    £50,000,000
    pre-money valuation

    1.96%
    equity available

    436
    investors

    £3,304
    pledge per investor

    06849691
    company number

    Administration
    company status

    17/03/2009
    incorporated 15 years

    Equity Calculator
    ?>
    Investment
    £
    Equity
    %
    Previous Funding rounds
    18 Apr 24 Crowdcube £1,440,500 / 144% 52.67%
    Officers

What the ratings mean

  • 49% and under
    We suggest potential investors carry out further study of their own
    50-64%
    Room for improvement
    65-79%
    Worth considering
    80%+
    Gold rating, our highest rating

RISK WARNING - The ratings are based on the information provided in the fund raiser’s pitch deck, business plans and financial forecasts which have appeared on a FCA regulated crowdfunding site. Where possible we validate the business plan to public sources such as LinkedIn, Companies House, Credit Agencies and internet searches. We cannot guarantee the information is correct. The ratings report takes no account of the investors/ individual circumstances. Do your own due diligence and get professional advice before investing. Your capital is at risk when investing in private companies.

Login to view the full report

Management 83%

Skills 82%
Hussle's management team covers all the key roles with skilled individuals, some of whom have received industry awards for their expertise.

0 comments

Log in to comment


Funding progress

Log in to view funding progress.


More from Health and Fitness

Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000

Log in to view amount pledged

    Log in to view target

    £50,000,000
    pre-money valuation

    1.96%
    equity available

    436
    investors

    £3,304
    pledge per investor

    06849691
    company number

    Administration
    company status

    17/03/2009
    incorporated 15 years

    Equity Calculator
    ?>
    Investment
    £
    Equity
    %
    Previous Funding rounds
    19 Apr 24 Crowdcube £1,440,500 / 144% 52.67%
    Officers
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph